Evidence map›Paper›PMID 41754610›Full record

ArticleViruses2026

Enhanced Antitumor Activity and Induction of Immunogenic Cell Death in NUT Carcinoma Cells by Combining Oncolytic Viruses with the Dual Inhibitor NEO2734.

Fiona D Nitschke, Julia Beil, Irina Smirnow, Andrea Schenk, Mary E Carter, Ulrich M Lauer, Linus D Kloker

Abstract read
In one paragraph

Article in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fiona D NitschkeDepartment of Medical Oncology and Pneumology, Virotherapy Center Tübingen (VCT), Medical University Hospital, 72076 Tübingen, Germany.ORCID 0009-0000-3119-423X
Julia BeilDepartment of Medical Oncology and Pneumology, Virotherapy Center Tübingen (VCT), Medical University Hospital, 72076 Tübingen, Germany.ORCID 0000-0002-6884-8249
Irina SmirnowDepartment of Medical Oncology and Pneumology, Virotherapy Center Tübingen (VCT), Medical University Hospital, 72076 Tübingen, Germany.
Andrea SchenkDepartment of Medical Oncology and Pneumology, Virotherapy Center Tübingen (VCT), Medical University Hospital, 72076 Tübingen, Germany.
Mary E CarterDepartment of Medical Oncology and Pneumology, Virotherapy Center Tübingen (VCT), Medical University Hospital, 72076 Tübingen, Germany.ORCID 0000-0002-9268-3640
Ulrich M LauerDepartment of Medical Oncology and Pneumology, Virotherapy Center Tübingen (VCT), Medical University Hospital, 72076 Tübingen, Germany.ORCID 0000-0002-4557-7730
Linus D KlokerDepartment of Medical Oncology and Pneumology, Virotherapy Center Tübingen (VCT), Medical University Hospital, 72076 Tübingen, Germany.ORCID 0000-0002-6709-9135

Funding

Deutsche Forschungsgemeinschaft (DFG, Germany Research Foundation) 514598620
6 · The paper itself

Abstract

NUT carcinoma (NC) is a rare exceptionally aggressive malignancy, defined by

Indexed as

Antineoplastic AgentsCarcinomaImmunogenic Cell DeathOncolytic VirotherapyOncolytic VirusesBiological ProductsBromodomain Containing ProteinsCell Line, TumorCell SurvivalCombined Modality TherapyHerpesvirus 1, HumanHumansMeasles virusTranscription FactorsAntineoplastic AgentsBiological ProductsBromodomain Containing Proteinstalimogene laherparepvecTranscription FactorsBET/p300 inhibitorimmunogenic cell deathMeV-GFPNEO2734NUT carcinomaoncolytic virusestalimogene laherparepvecT-VECvirotherapy

Identifiers

PMID41754610
PMCPMC12945177

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.